Australia markets open in 4 hours 5 minutes

Twist Bioscience Corporation (TWST)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
56.47-2.19 (-3.72%)
As of 03:55PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close58.66
Open57.17
Bid56.23 x 600
Ask56.71 x 600
Day's range55.68 - 59.54
52-week range14.42 - 59.54
Volume748,997
Avg. volume1,167,608
Market cap3.288B
Beta (5Y monthly)1.80
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024

    SOUTH SAN FRANCISCO, Calif., July 11, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, before the opening of the market on Friday, August 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time

  • Business Wire

    Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies

    SOUTH SAN FRANCISCO, Calif., July 10, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its high-throughput antibody portfolio with the launch of a CHO cell line for Twist Express Antibodies. Twist also offers HEK293 expression Twist Express Antibodies.

  • Business Wire

    Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A

    SOUTH SAN FRANCISCO, Calif., July 09, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its growing portfolio of synthetic viral controls with the launch of a synthetic RNA control for H5N1 Influenza A, which is one of the causes of Highly Pathogenic Avian Influenza (HPAI) or bird flu, covering 99.9% of hemagglutinin (HA) and neuraminidase (NA)